A 56-year-old woman from China facing a rare and aggressive metaplastic breast cancer received renewed hope through a remote second opinion from MSKCC, coordinated by Medebound HEALTH. The expert consultation led to a personalized treatment plan involving antibody-drug conjugates, immunotherapy, and a detailed monitoring strategy, demonstrating the power of international collaboration in complex cancer care.